Epidemiology of Screening‑ targeted Cancers According to New Data of the Czech National Cancer Registry
Authors:
L. Dušek 1,2; J. Mužík 1,2; D. Malúšková 1; O. Májek 1,2; T. Pavlík 1; J. Koptíková 1; J. Gregor 1; P. Brabec 1; J. Abrahámová 3
Authors place of work:
Institut bio statistiky a analýz, LF a PřF MU, Brno
1; Ústav zdravotnických informací a statistiky ČR, Praha
2; Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
3
Published in the journal:
Klin Onkol 2014; 27(Supplementum 2): 19-39
doi:
https://doi.org/10.14735/amko20142S19
Summary
The Czech Society for Oncology has developed an information system which combines the population-based Czech National Cancer Registry with clinical databases in order to cover the main areas of health care assessment – monitoring of the population burden, prediction of the number of cancer patients, diagnostic and treatment results. The presented data demonstrate a high cancer burden within the Czech population – each year there are approximately 8,000 new cases of colorectal cancer, 6,500 new cases of breast cancer, and 1,000 new cases of cervical cancer. And each year, about 4,000 people die from colorectal cancer, around 2,000 women die from breast cancer, and approximately 400 women die from cervical cancer in the Czech Republic. Population-based screening programmes focus on all of the above-mentioned groups of malignant tumours; therefore, it is essential to monitor epidemiological trends in order to assess the screening impact. Despite the high incidence rates of all three cancer types, the trend in mortality rates has been stable or has even decreased in the long term, which has inevitably led to a significant increase in the total prevalence of cancer patients. In 2011, the prevalence of colorectal cancer, breast cancer and cervical cancer amounted to 51,064 people, 67,261 women and 17,398 women, respectively. When compared with the year 2001, there was a 59%, 69% and 25% increase in the prevalence of colorectal cancer, breast cancer, and cervical cancer, respectively. Undoubtedly, taking care of high numbers of cancer patients will continue to require significant financial resources in the near future. As the epidemiological burden is still on the increase, preventive programmes need to be further promoted, including secondary prevention, which is provided through organised screening programmes. Although effective methods exist for timely diagnosis of all three of the above-mentioned cancer types, the epidemiological situation in the Czech Republic is being steadily worsened by a relatively high proportion of primary cancers being diagnosed too late. Each year, more than 50% of new colorectal cancer cases are diagnosed in clinical stage III or higher; in cervical cancer, this proportion is nearly 35%. By contrast, the well-promoted breast cancer screening programme has led to more than 75% of new cases of breast cancer being diagnosed in stages I or II, when the chance of successful treatment is significantly higher.
Key words:
epidemiology – colorectal carcinoma – breast carcinoma – cervical carcinoma
This study was supported by the project 36/14//NAP “Development and implementation of methodology for the evaluation of effectiveness of personalised invitations of citizens to cancer screening programmes” as part of the programme of the Czech Ministry of Health “National action plans and conceptions”.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
1. 9. 2014
Accepted:
17. 10. 2014
Zdroje
1. Ferlay J, Steliarova‑ Foucher E, Lortet‑ Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6): 1374– 1403. doi: 10.1016/ j.ejca.2012.12.027.
2. Ferlay J, Soerjomataram I, Ervik M et al (eds). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [monograph on the Internet]. Lyon: International Agency for Research on Cancer; 2013 [cited 2014 May 6]. Available from: http:/ / globocan.iarc.fr.
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16(3): 481– 488.
4. Curado MP, Edwards B, Shin HR et al (eds). Cancer Incidence in Five Continents. Vol. IX. IARC Scientific Publications No. 160 [monograph on the Internet]. Lyon: IARC; 2007 [cited 2013 May 8]. Available from: http:/ / ci5.iarc.fr.
5. Ferlay J, Parkin DM, Steliarova‑ Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46(4): 765– 781. doi: 10.1016/ j.ejca.2009.12.014.
6. Dušek L (ed.). Czech Cancer Care in Numbers 2008– 2009. Praha: Grada Publishing 2009.
7. Franco EL, Correa P, Santella RM et al. Role and limitations of epidemiology in establishing a causal association. Semin Cancer Biol 2004; 14(6): 413– 426.
8. Uzis.cz [internetová stránka]. Ústav zdravotnických informací a statistiky ČR. Národní onkologický registr (NOR) [citováno 29. srpna 2014]. Dostupný z: http:/ / www.uzis.cz/ registry‑ nzis/ nor.
9. Dušek L, Mužík J, Kubásek M et al (eds). Epidemiologie zhoubných nádorů v České republice [monografie na Internetu]. Brno: Masarykova univerzita; 2005 [citováno 30. srpna 2014]. Dostupný z: http:/ / www.svod.cz.
10. Demografická příručka 2007. Český statistický úřad, 2008 [citováno 30. srpna 2014]. Dostupné z: http:/ / www.czso.cz/ csu/ 2008edicniplan.nsf/ publ/ 4032- 08- 2007.
11. University of California Berkeley, Max Planck Institute for Demographic Research. Human Mortality Database [cited 2014 Aug 11]. Available from: http:/ / www.mortality.org.
12. Waterhouse J, Muir CS, Shanmugaratnam K et al (eds). Cancer incidence in five continents. Vol IV. IARC Scientific Publications No. 42. Lyon: IARC 1982.
13. Adami HO, Hunter D, Trichopoulos D (eds). Textbook of cancer epidemiology. New York: Oxford University Press 2002.
14. Waterhouse J, Muir CS, Correa P et al (eds). Cancer incidence in five continents. Vol. III. IARC Scientific Publications No. 15. Lyon: IARC 1976.
15. Pavlík T, Dušek L, Májek O et al. Five‑year survival rates of cancer patients in the Czech Republic. In: Dušek L (ed.). Czech cancer care in numbers 2008– 2009. Praha: Grada Publishing 2009.
16. Pavlík T, Májek O, Mužík J et al. Estimating the number of colorectal cancer patients treated with anti‑tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health 2012; 12: 117. doi: 10.1186/ 1471‑ 2458‑ 12‑ 117.
17. Breslow NE, Day NE. Statistical methods in cancer research. Vol. II – The design and analysis of cohort studies. Lyon: IARC 1987.
18. Bray F, Guilloux A, Sankila R et al. Practical implications of imposing a new world standard population. Cancer Causes Control 2002; 13(2): 175– 182.
19. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101– 121.
20. Pavlík T, Májek O, Büchler T et al. Trends in stage‑ specific population‑based survival of cancer patients in the Czech Republic in the period 2000– 2008. Cancer Epidemiol 2014; 38(1): 28– 34.
21. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999– 2007 by country and age: results of EUROCARE‑ 5 – a population‑based study. Lancet Oncol 2014; 15(1): 23– 34. doi: 10.1016/ S1470‑ 2045(13)70546‑ 1.
22. Arbyn M, Anttila A, Jordan J et al (eds). European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: European Communities 2008.
23. Karsa L, Anttila A, Ronco G et al (eds). Cancer Screening in the European Union: report on the implementation of the Council Recommendation on cancer screening. Luxembourg: European Communities 2008.
24. Perry N, Broeders M, de Wolf C et al (eds). European guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed. Luxembourg: Office for Official Publications of the EC 2006.
25. Segnan N, Patnick J, von Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: Publications Office of the European Union 2010.
26. Dušek L, Zavoral M, Májek O et al (eds). Kolorektum.cz – Program kolorektálního screeningu v České republice [monografie na Internetu]. Brno: Masarykova univerzita; 2014 [citováno 29. srpna 2014]. Dostupné z: http:/ / www.kolorektum.cz.
27. Májek O, Daneš J, Skovajsová M et al (eds). Mamo.cz – Program mamografického screeningu v České republice [monografie na internetu]. Brno: Masarykova univerzita; 2014 [citováno 29. srpna 2014]. Dostupné z: http:/ / www.mamo.cz.
28. Májek O, Dvořák V, Dušek L et al. Cervix.cz – Program cervikálního screeningu v České republice [monografie na Internetu]. Brno: Masarykova univerzita; 2014 [citováno 29. srpna 2014]. Dostupné z: http:/ / www.cervix.cz.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2014 Číslo Supplementum 2
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Najčítanejšie v tomto čísle
- Performance Indicators in Screening Programmes
- Results of the Czech National Cervical Cancer Screening Programme
- Results of the Czech National Breast Cancer Screening Programme
- Epidemiology of Screening‑ targeted Cancers According to New Data of the Czech National Cancer Registry